In U.S. clinical studies the ProCol ^® bioprosthesis demonstrated improved patency compared with ePTFE grafts. ProCol ^® succeeded where others had failed, with some patients ProCol ^® grafts still patent after 5 years.

The ProCol^® Bioprosthesis is stored in sterile saline, so preparation in the operating room is easily accomplished via a simple, quick rinsing process

ProCol^® is highly biocompatible and elicits no antibody reactions

Handling and suturing characteristics are similar to the patient's native tissue making it easy to work with during the implant procedure.

The natural tissue is easily punctured in the hemodialysis setting - affording the ease of access associated with a native fistula. Hemostasis is also readily achieved with minimal pressure following the removal of the hemodialysis needles.

The ProCol^® graft may be accessed for hemodialysis as soon as two weeks following implant, based upon the physician's decision and patient tolerance

Highly elastic and compliant ProCol^® is capable of handling high flow rates